Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment

British Journal of Clinical Pharmacology

Volumn 78, Issue 3, 2014, Pages 649-659

  Van Staa, Tjeerd P ^a,b   Carr, Daniel F ^c   O'Meara, Helen ^c   McCann, Gerry ^d   Pirmohamed, Munir ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

cardiovascular disease; creatinine; phosphokinase; rhabdomyolysis; statins

Indexed keywords

ALLOPURINOL; ATORVASTATIN; BISOPROLOL FUMARATE; CERIVASTATIN; CLOPIDOGREL; CREATINE KINASE; CYTOCHROME P450 3A4; EZETIMIBE; FLUINDOSTATIN; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; CYTOCHROME P450 3A; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; FACTUAL DATABASE; GREAT BRITAIN; METABOLISM; MIDDLE AGED; PRIMARY HEALTH CARE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; CREATINE KINASE; CYTOCHROME P-450 CYP3A; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PYRIMIDINES; RHABDOMYOLYSIS; RISK FACTORS; ROSUVASTATIN CALCIUM; SULFONAMIDES;

EID: 84906508423     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12367     Document Type: Article

References (27)

1. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S,. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; (1) CD004816.
2. Gutierrez J, Ramirez G, Rundek T, Sacco RL,. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med 2012; 172: 909-919.
3. Harper CR, Jacobson TA,. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18: 401-408. (Pubitemid 47051918)
4. Jamal SM, Eisenberg MJ, Christopoulos S,. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004; 147: 956-965. (Pubitemid 38880948)
5. Sewright KA, Clarkson PM, Thompson PD,. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007; 9: 389-396. (Pubitemid 350104239)
6. Laaksonen R,. On the mechanisms of statin-induced myopathy. Clin Pharmacol Ther 2006; 79: 529-531. (Pubitemid 43817946)
7. Chapman MJ, Carrie A,. Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway? Arterioscler Thromb Vasc Biol 2005; 25: 2441-2444. (Pubitemid 43732261)
8. Owczarek J, Jasińska M, Orszulak-Michalak D,. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 2013; 57: 23-34.
9. Baker SK,. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005; 31: 572-580. (Pubitemid 40577779)
10. Hanai J, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, Lecker SH,. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007; 117: 3940-3951. (Pubitemid 350224103)
11. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R,. SLCO1B1 variants and statin-induced myopathy- A genomewide study. N Engl J Med 2008; 359: 789-799.
12. Williams T, van Staa TP, Puri S, Eaton S,. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 2012; 3: 89-99.
13. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ,. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
14. Carr DF, O'Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, van Staa T, Pirmohamed M,. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof of concept study using the clinical practice research datalink (CPRD). Clin Pharmacol Ther 2013; 94: 695-701.
15. Thompson PD, Clarkson P, Karas RH,. Statin-associated myopathy. JAMA 2003; 289: 1681-1690. (Pubitemid 37430274)
16. Molokhia M, McKeigue P, Curcin V, Majeed A,. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. PLoS ONE 2008; 3: e2522.
17. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
18. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-1342.
19. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH,. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003; 163: 688-692. (Pubitemid 36343361)
20. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R,. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-2590. (Pubitemid 39577514)
21. Floyd JS, Heckbert SR, Weiss NS, Carrell DS, Psaty BM,. Use of administrative data to estimate the incidence of statin-related rhabdomyolysis. JAMA 2012; 307: 1580-1582.
22. Chang C-H, Kusama M, Ono S, Sugiyama Y, Orii T, Akazawa M,. Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information. BMJ Open 2013; 3: pii: e002040.
23. Egan A, Colman E,. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med 2011; 365: 285-287.
24. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A,. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013; 158: 526-534.
25. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD,. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33: 171-187.
26. Floyd JS, Kaspera R, Marciante KD, Weiss NS, Heckbert SR, Lumley T, Wiggins KL, Tamraz B, Kwok P-Y, Totah RA, Psaty BM,. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin Pharmacol Ther 2012; 91: 896-904.
27. Patel AM, Shariff S, Bailey DG, Juurlink DN, Gandhi S, Mamdani M, Gomes T, Fleet J, Hwang YJ, Garg AX,. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med 2013; 158: 869-876.